Effect of paricalcitol on circulating parathyroid hormone in X-linked hypophosphatemia: A randomized, double-blind, placebo-controlled study

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 9, 2014, Pages 3103-3111

  Carpenter, Thomas O ^a   Olear, Elizabeth A ^a   Zhang, Jane H ^b   Ellis, Bruce K ^a   Simpson, Christine A ^a   Cheng, David ^a   Gundberg, Caren M ^a   Insogna, Karl L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; CREATININE; FIBROBLAST GROWTH FACTOR 23; MEDRONATE TECHNETIUM TC 99M; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; PHOSPHORUS; PLACEBO; 1,25-DIHYDROXYVITAMIN D; BONE DENSITY CONSERVATION AGENT; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR; VITAMIN D;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BONE CHARACTERISTICS AND FUNCTIONS; BONE SCINTISCANNING; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CHILD; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG POTENTIATION; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEMALE; GLOMERULUS FILTRATION RATE; HORMONE INHIBITION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERPARATHYROIDISM; MALE; MORNING DOSAGE; OUTCOME ASSESSMENT; PHOSPHATE BLOOD LEVEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RENAL PHOSPHATE THRESHOLD PER GLOMERULAR FILTRATION RATE; SCHOOL CHILD; SIDE EFFECT; TREATMENT OUTCOME; UNITED STATES; VITAMIN BLOOD LEVEL; X LINKED HYPOPHOSPHATEMIC RICKETS; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; COMPLICATION; FAMILIAL HYPOPHOSPHATEMIC RICKETS; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALKALINE PHOSPHATASE; BONE DENSITY CONSERVATION AGENTS; CHILD; DOUBLE-BLIND METHOD; ERGOCALCIFEROLS; FAMILIAL HYPOPHOSPHATEMIC RICKETS; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERPARATHYROIDISM; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; PLACEBOS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VITAMIN D; YOUNG ADULT;

EID: 84907210974     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2017     Document Type: Article

References (23)

1. Burnett CH, Dent CE, Harper C, Warland BJ. Vitamin D-resistant rickets. Am J Med. 1964; 36: 222-232.
2. Holm IA, Econs MJ, Carpenter TO. Familial hypophosphatemia and related disorders. In: Glorieux FH, Juppner H, Pettifor JM, eds. Pediatric Bone: Biology, Diseases. 2nd ed. San Diego: Elsevier; 2012: 699-726
3. Alon U, Chan JC. Effects of parathyroid hormone and 1,25-dihydroxyvitamin D3 on tubular handling of phosphate in hypophosphatemic rickets. J Clin Endocrinol Metab. 1984; 58: 671-675.
4. Carpenter TO, Mitnick MA, Smith C, Ellison A, Insogna KL. Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia. J Clin Endocrinol Metab. 1994; 78: 1378-1383.
5. Firth RG, Grant CS, Riggs BL. Development of hypercalcemic hyperparathyroidism after long-Term phosphate supplementation in hypophosphatemic osteomalacia. Report of two cases. Am J Med. 1985; 78: 669-773.
6. Knudtzon J, Halse J, Monn E, et al. Autonomous hyperparathy-roidism in X-linked hypophosphataemia. Clin Endocrinol (Oxf). 1995; 42: 199-203.
7. Andrukhova O, Zeitz U, Goetz R, Mohammadi M, Lanske B, Erben RG. FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2-SGK1 signaling pathway. Bone. 2012; 51: 621-628.
8. Lyles KW, Burkes EJ Jr, McNamara CR, Harrelson JM, Pickett JP, DreznerMK.The concurrence of hypoparathyroidism provides new insights to the pathophysiology of X-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 1985; 60: 711-717.
9. Galitzer H, Ben-Dov I, Lavi-Moshayoff V, Naveh-Many T, Silver J. Fibroblast growth factor 23 acts on the parathyroid to decrease parathyroid hormone secretion. Curr Opin Nephrol Hypertens. 2008; 17: 363-367.
10. Carpenter TO, Insogna KL, Zhang JH, et al. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment and relationship to parathyroid status. J Clin Endocrinol Metab. 2010; 95: E352-E357.
11. Bettinelli A, Bianchi ML, Mazzucchi E, Gandolini G, Appiani AC. Acute effects of calcitriol and phosphate salts on mineral metabolism in children with hypophosphatemic rickets. J Pediatr. 1991; 118: 372-376.
12. Martin KJ, González EA, Gellens ME, Hamm LL, Abboud H, Lindberg J. Therapy of secondary hyperparathyroidism with 19-nor-1-,25-dihydroxyvitamin D2. Am J Kidney Dis. 1998; 32: S61-S66.
13. Robinson DM, Scott LJ. Paricalcitol: a review of its use in the management of secondary hyperparathyroidism. Drugs. 2005; 65: 559-576.
14. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003; 24: 1656-1663.
15. Aono Y, Yamazaki Y, Yasutake J, Kawata T, Hasegawa H, Urakawa I, Fujita T, Wada M, Yamashita T, Fukumoto S, Shimada T. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res. 2009; 24: 1879-1888.
16. Bergwitz C, Jüppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med. 2010; 61: 91-104.
17. Farrow EG, White KE. Recent advances in renal phosphate handling. Nat Rev Nephrol. 2010; 6: 207-217.
18. Bai X, Miao D, Goltzman D, Karaplis AC. Early lethality in Hyp mice with targeted deletion of Pth gene. Endocrinology. 2007; 148: 4974-4983.
19. Alon US, Levy-Olomucki R, Moore WV, Stubbs J, Liu S, Quarles LD. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol. 2008; 3: 658-664.
20. Raeder H, Shaw N, Netelenbos C, Bjerknes R. A case of X-linked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet. Eur J Endocrinol. 2008; 159: S101-S105.
21. Yavropoulou MP, Kotsa K, Gotzamani Psarrakou A, et al. Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review. Hormones. 2010; 9: 274-278.
22. US Food and Drug Administration. Sensipar (cinacalcet hydrochloride): Drug Safety Communication. FDA suspends pediatric clinical trials after report of death. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm341255. htm Published February 26, 2013. July 19, 2014.
23. Moltz KC, Friedman AH, Nehgme RA, Kleinman CS, Carpenter TO.Ectopic cardiac calcification associated with hyperparathyroidism in a boy with hypophosphatemic rickets. Curr Opin Pediatr. 2001; 13: 373-375.